Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 5 of 5 results for oseltamivir

  1. Amantadine, oseltamivir and zanamivir for the treatment of influenza (TA168)

    Evidence-based recommendations on amantadine (Lysovir), oseltamivir (Tamiflu) and zanamivir (Relenza) for treating influenza in children and adults.

    Technology appraisal guidance
    Published
    25 February 2009
    View recommendations

    Sections for TA168

  2. Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza (TA158)

    Evidence-based recommendations on oseltamivir (Tamiflu), amantadine (Lysovir or Symmetrel) or zanamivir (Relenza) to prevent influenza (flu).

    Technology appraisal guidance
    Published
    24 September 2008
    View recommendations

    Sections for TA158

  3. Flu treatment - zanamivir, amantadine and oseltamivir (TA58)

    This guidance has been updated and replaced by NICE technology appraisal guidance 168.

    Technology appraisal guidance
    Published
    26 February 2003

  4. The clinical effectiveness and cost effectiveness of amantadine and oseltamivir for the prophylaxis of influenza (TA67)

    This guidance has been updated and replaced NICE technology appraisal guidance 158.

    Technology appraisal guidance
    Published
    24 September 2003

  5. Past appeals and decisions

    Past technology appraisal appeals and decisions